245 related articles for article (PubMed ID: 37111613)
1. Lipid Nanoparticles as Promising Carriers for mRNA Vaccines for Viral Lung Infections.
Hajiaghapour Asr M; Dayani F; Saedi Segherloo F; Kamedi A; Neill AO; MacLoughlin R; Doroudian M
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111613
[TBL] [Abstract][Full Text] [Related]
2. From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases.
Pilkington EH; Suys EJA; Trevaskis NL; Wheatley AK; Zukancic D; Algarni A; Al-Wassiti H; Davis TP; Pouton CW; Kent SJ; Truong NP
Acta Biomater; 2021 Sep; 131():16-40. PubMed ID: 34153512
[TBL] [Abstract][Full Text] [Related]
3. Chemistry of Lipid Nanoparticles for RNA Delivery.
Eygeris Y; Gupta M; Kim J; Sahay G
Acc Chem Res; 2022 Jan; 55(1):2-12. PubMed ID: 34850635
[TBL] [Abstract][Full Text] [Related]
4. Recent Advances in the Lipid Nanoparticle-Mediated Delivery of mRNA Vaccines.
Swetha K; Kotla NG; Tunki L; Jayaraj A; Bhargava SK; Hu H; Bonam SR; Kurapati R
Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992242
[TBL] [Abstract][Full Text] [Related]
5. Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing.
Qiu M; Li Y; Bloomer H; Xu Q
Acc Chem Res; 2021 Nov; 54(21):4001-4011. PubMed ID: 34668716
[TBL] [Abstract][Full Text] [Related]
6. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses.
Zeng Y; Escalona-Rayo O; Knol R; Kros A; Slütter B
Biomater Sci; 2023 Jan; 11(3):964-974. PubMed ID: 36537916
[TBL] [Abstract][Full Text] [Related]
7. Lipid Nanoparticle-mRNA Formulations for Therapeutic Applications.
Wang C; Zhang Y; Dong Y
Acc Chem Res; 2021 Dec; 54(23):4283-4293. PubMed ID: 34793124
[TBL] [Abstract][Full Text] [Related]
8. Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines.
Aldosari BN; Alfagih IM; Almurshedi AS
Pharmaceutics; 2021 Feb; 13(2):. PubMed ID: 33540942
[TBL] [Abstract][Full Text] [Related]
9. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications.
Lopes C; Cristóvão J; Silvério V; Lino PR; Fonte P
Expert Opin Drug Deliv; 2022 Oct; 19(10):1381-1395. PubMed ID: 36223174
[TBL] [Abstract][Full Text] [Related]
10. The role of lipid components in lipid nanoparticles for vaccines and gene therapy.
Hald Albertsen C; Kulkarni JA; Witzigmann D; Lind M; Petersson K; Simonsen JB
Adv Drug Deliv Rev; 2022 Sep; 188():114416. PubMed ID: 35787388
[TBL] [Abstract][Full Text] [Related]
11. Recent Advances in Messenger Ribonucleic Acid (mRNA) Vaccines and Their Delivery Systems: A Review.
Yihunie W; Nibret G; Aschale Y
Clin Pharmacol; 2023; 15():77-98. PubMed ID: 37554660
[TBL] [Abstract][Full Text] [Related]
12. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
[TBL] [Abstract][Full Text] [Related]
13. Delivery Strategies for mRNA Vaccines.
Ramachandran S; Satapathy SR; Dutta T
Pharmaceut Med; 2022 Feb; 36(1):11-20. PubMed ID: 35094366
[TBL] [Abstract][Full Text] [Related]
14. Lipid nanoparticle formulations for optimal RNA-based topical delivery to murine airways.
Tam A; Kulkarni J; An K; Li L; Dorscheid DR; Singhera GK; Bernatchez P; Reid G; Chan K; Witzigmann D; Cullis PR; Sin DD; Lim CJ
Eur J Pharm Sci; 2022 Sep; 176():106234. PubMed ID: 35688311
[TBL] [Abstract][Full Text] [Related]
15. An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates.
Ripoll M; Bernard MC; Vaure C; Bazin E; Commandeur S; Perkov V; Lemdani K; Nicolaï MC; Bonifassi P; Kichler A; Frisch B; Haensler J
Biomaterials; 2022 Jul; 286():121570. PubMed ID: 35576809
[TBL] [Abstract][Full Text] [Related]
16. mRNA delivery technologies: Toward clinical translation.
Gómez-Aguado I; Rodríguez-Castejón J; Beraza-Millor M; Rodríguez-Gascón A; Del Pozo-Rodríguez A; Solinís MÁ
Int Rev Cell Mol Biol; 2022; 372():207-293. PubMed ID: 36064265
[TBL] [Abstract][Full Text] [Related]
17. Production, Characterization, and Assessment of Permanently Cationic and Ionizable Lipid Nanoparticles for Use in the Delivery of Self-Amplifying RNA Vaccines.
Kairuz D; Samudh N; Ely A; Arbuthnot P; Bloom K
Pharmaceutics; 2023 Apr; 15(4):. PubMed ID: 37111658
[TBL] [Abstract][Full Text] [Related]
18. Characterization of Lipid Nanoparticles Containing Ionizable Cationic Lipids Using Design-of-Experiments Approach.
Terada T; Kulkarni JA; Huynh A; Chen S; van der Meel R; Tam YYC; Cullis PR
Langmuir; 2021 Jan; 37(3):1120-1128. PubMed ID: 33439022
[TBL] [Abstract][Full Text] [Related]
19. Testing the In Vitro and In Vivo Efficiency of mRNA-Lipid Nanoparticles Formulated by Microfluidic Mixing.
El-Mayta R; Padilla MS; Billingsley MM; Han X; Mitchell MJ
J Vis Exp; 2023 Jan; (191):. PubMed ID: 36744791
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery.
Maeki M; Uno S; Niwa A; Okada Y; Tokeshi M
J Control Release; 2022 Apr; 344():80-96. PubMed ID: 35183654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
